Public administration and R&D localisation by pharmaceutical and biotech companies: A theoretical framework and the Italian case-study
Authors:
- 7 July 2006
- journal article
- Published by Elsevier in Health Policy
- Vol. 81 (1) , 117-130
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Strategic R&D Location by Multinational Firms: Spillovers, Technology Sourcing, and CompetitionSSRN Electronic Journal, 2006
- Research and development costs for drugsThe Lancet, 2004
- Institutional frameworks and innovation in the German and UK pharmaceutical industryResearch Policy, 2003
- The price of innovation: new estimates of drug development costsJournal of Health Economics, 2003
- Pharmaceutical patents and price controlsClinical Therapeutics, 2002
- Regulating Drug Prices: Where Do We Go from Here?Fiscal Studies, 1998
- Future European health care: cost containment, health care reform and scientific progress in drug researchThe International Journal of Health Planning and Management, 1997
- The Societal Value of PharmaceuticalsPharmacoEconomics, 1996
- Influences on R&D growth among Japanese pharmaceutical firms, 1975–1990The Journal of High Technology Management Research, 1995
- Implicit Industrial Policy: The Triumph of Britain and the Failure of France in Global PharmaceuticalsIndustrial and Corporate Change, 1994